^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Waldenstrom Macroglobulinemia

    Related cancers:
    23h
    BGB-3111-215t: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Trial completion date: Oct 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    3d
    Avoiding serious treatment-emergent adverse events in Waldenström macroglobulinemia patients. (PubMed, Expert Rev Hematol)
    Post Bruton's tyrosine kinase inhibitors, novel therapies and combinations are being investigated. Ongoing work on issues of quality of life and patient reported outcomes will better inform our understanding of patient experience and should be reported in clinical trials.
    Review • Journal • Adverse events
    |
    TP53 (Tumor protein P53) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    7d
    KEYNOTE145: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Calquence (acalabrutinib)
    13d
    ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Shayna Sarosiek, MD | Recruiting --> Active, not recruiting | N=33 --> 12
    Enrollment closed • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule) • IL2RA (Interleukin 2 receptor, alpha) • CD5 (CD5 Molecule) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • MME (Membrane Metalloendopeptidase) • ITGAE (Integrin Subunit Alpha E) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Rituxan (rituximab) • Calquence (acalabrutinib)
    13d
    ECWM-2: Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, Christian Buske | Trial completion date: Sep 2029 --> Feb 2027
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib
    14d
    Solitary Hepatic Plasmacytoma With IgM Monoclonal Gammopathy: A Case Report. (PubMed, Case Rep Hematol)
    The patient demonstrated excellent clinical and radiographic response to zanubrutinib therapy by way of improvement in IgM and the size of the liver mass...To our knowledge, this represents one of the few documented cases of IgM-secreting solitary hepatic plasmacytoma. This case highlights diagnostic challenges, the importance of immunophenotypic profiling, and the need for individualized management strategies in this rare entity.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PAX5 (Paired Box 5) • SDC1 (Syndecan 1)
    |
    Brukinsa (zanubrutinib)
    14d
    BELLWAVE-003: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (clinicaltrials.gov)
    P2, N=490, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2027 --> Jan 2029 | Trial primary completion date: Mar 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    TP53 mutation • Chr t(11;14)
    |
    nemtabrutinib (MK-1026)
    15d
    Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia. (PubMed, Haematologica)
    Not available.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    16d
    ZBR in WM: A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia (clinicaltrials.gov)
    P2, N=43, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine
    22d
    NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    22d
    A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia (clinicaltrials.gov)
    P4, N=18, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Brukinsa (zanubrutinib)
    23d
    This Study is Designed to Characterize the Safety, Tolerability, and Anti-tumor Activity of MDX2003 in Patients With Different Types of Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Not yet recruiting, ModeX Therapeutics, An OPKO Health Company
    New P1/2 trial